GRK2 and atherosclerosis: Notably, treatment with paroxetine, a chemical GRK2 inhibitor, significantly reduced OSS‐induced vascular endothelial dysfunction, suggesting that GRK2 could be a potential target for developing new drugs to treat atherosclerosis in the future.